Recently, the implication of biocompatible nanotechnologies has set the stage for an evolutionary leap in diagnostic imaging and therapy. In this scope, the book presents a comprehensive overview of the possible causes, diagnostic criteria, and treatment assessments of amyotrophic lateral sclerosis, and presents the recent findings using innovative, highly sensitive, and novel diagnostic molecular imaging approaches. In addition, the book offers new perspectives of an innovative and recently developed approach in neuroimaging using surface-enhanced nanoimaging microscopy, which can be a promising technique for early diagnosis and treatment assessments.
- Covers a comprehensive overview of the recent findings on amyotrophic lateral sclerosis
- Highlights the latest and advanced diagnostic and therapeutic approaches with respect to neuronanomedicine
- Discusses the future challenges of cell replacement and gene therapy
- Is illustrated throughout with excellent figures and has references to accompany each section
Table of Contents
Clinical Features of Amyotrophic Lateral Sclerosis
The influence of environmental factors
Diagnostic Criteria of Amyotrophic Lateral Sclerosis
Perspectives of Neuro-Nanomedicine
Nanomedicine and Neurodegenerative Diseases
In vivo and in vitro nano-based diagnostic Approaches
Nanocarriers and CNS targeted drug delivery
Nanotechnology for CNS Regeneration and Future Direction
ALS Novel Therapeutic Approaches
Occupational and Supportive Therapy
Future Challenges of cell replacement and Gene therapy.
Prof Lina Machtoub received her Ph.D. from the University of Tokyo, Japan, 2002, after she was granted honourable research fellowship from the Japanese Government for 5 years. In 2003, she joined Max Planck Institute, Germany, after she was granted a research award from Alexander von Humboldt foundation. In the institute, she worked on the development of combined ultra-high magnetic field and optical imaging. In 2006, she became visiting scientist at Harvard Medical University, Boston. Since 2007, she has participated in several clinical research projects focusing on the development of clinical multimodal imaging techniques based on nanobiotechnology. In 2009, she joined the Medical University of Innsbruck, Austria, where she conducted research on developing highly sensitive, diagnostic, and targeted imaging probes with implications of in vivo imaging-targeted contrast agents and multifunctional imaging. Her main project was the development of innovative diagnostic approach "surface-enhanced coherent anti-Stokes Raman scattering (SECARS) microscopy" using nanoscale contrast agents for magnetic resonance.